|
|
|
By Edward Ahn, MEDIPOST Inc. | Mesenchymal stem cells offer a promising path forward in managing complex conditions that are often age-related. What makes MSCs unique and how do they compare to iPSCs? | |
|
|
|
|
| Meet Singota's 'Dr. Impossible' | Article | Singota Solutions | Explore how Dr. Shehaab Savliwala, a leading formulation scientist at Singota Solutions, transforms complex pharmaceutical challenges into breakthroughs in nanoparticle formulations. |
|
|
| Investing In Capacity – API Commercial Manufacturing | Case Study | Cambrex | A pharma company sought a CMO partner with commercial manufacturing capabilities and expertise as well as exemplary quality systems to find a cost-effective process to produce the API for a new drug. |
|
|
| Humanizing High-Affinity Antibodies for Transmembrane Proteins | Poster | By Vydehi Kanneganti, Nicole Polewaczyk, Roger Wong, and Brian A. Zabel, Curia | Here, we present a hybridoma-based antibody discovery and humanization strategy for a T1P target, utilizing Penta Mice immunization to generate monoclonal antibodies. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
